Dubovsky succeeds Fries as Novavax CMO; plus Carl June to head Ziopharm SAB, Dewpoint, FerGene, Cambrex, Adverum, Epsilen and more
Novavax Inc. (NASDAQ:NVAX), which expects Phase I data for its COVID-19 vaccine in July, hired Filip Dubovsky as SVP and CMO. He succeeds CMO Louis Fries, who has retired. Dubovsky was head of clinical engagement and policy and deputy CMO for clinical affairs at AstraZeneca plc (LSE:AZN; NYSE:AZN). The vaccines company also named Silvia Taylor as SVP, investor relations and corporate affairs; she was VP of global corporate affairs and communications at Autolus Therapeutics plc (NASDAQ:AUTL).
CAR T pioneer Carl June will lead the newly formed scientific advisory board of Ziopharm Oncology Inc. (NASDAQ:ZIOP). He is director of both the Parker Institute for Cancer Immunotherapy and the Center for Cellular Immunotherapies at the University of Pennsylvania’s Perelman School of Medicine...